![]() |
同义名 : | - |
CAS号 : | 1429054-28-3 | |
货号 : | A103226 | |
分子式 : | C23H32N2O2 | |
纯度 : | 99%+ | |
分子量 : | 368.51 | |
MDL号 : | MFCD31619285 | |
存储条件: |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
溶解度 : | - | |
动物实验配方: |
生物活性 | |||
---|---|---|---|
描述 | Hypoxia-inducible factor (HIF)-1α/β heterodimer binds to the hypoxia-response element (HRE) to induce the transcription of genes related to angiogenesis, metastasis, and resistance in human cancers. IDF-11774 reduced the HRE-luciferase activity of HIF-1α with an IC50 value of 3.65 μM. It also inhibited the accumulation of HIF-1α accumulation under hypoxic conditions in HCT116 human colon cancer cells at the doses of 5-20 μM. Treatment of human umbilical vascular endothelial cells with 20 μM IDF-11774 resulted in a reduction of capillary network formation on Matrigel as compared to DMSO-treated controls. IDF-11774 at 20 μM also decreased the mRNA expression of GLUT1 and pyruvate dehydrogenase kinase, and suppressed the cellular uptake of [3H]2-deoxyglucose in HCT116 cells. Twelve-hour treatment with 10 μM IDF-11774 significantly reduced the levels of intracellular lactate, NAD+ and NADP+. In mice inoculated with HCT116 cells, daily oral administration of IDF-11774 (10, 30, or 60 mg/kg/day) for two weeks significantly inhibited tumor growth at a dose-dependent manner in comparison to vehicle-treated controls[3]. Mechanism: IDF-11774 is a novel HIF-1 inhibitor that suppresses the accumulation of HIF-1α both in vitro and in vivo[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.71mL 0.54mL 0.27mL |
13.57mL 2.71mL 1.36mL |
27.14mL 5.43mL 2.71mL |
参考文献 |
---|